Jennifer Yannucci, MD
Hematology & Oncology · Savannah, GANPI 1861477721
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (34.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Novartis at 37.8% of the total. 2025 is the largest year on record at $1,993, 3.7 times the $540 reported in 2019.
Across 97 payments — averaging $64.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Rigel Pharmaceuticals, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$872
- Bristol Myers Squibb$300
- Gilead$251
- Merck$175
- plus $1K from 23 others
Across 3 payments — averaging $9479.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$28K
- Merck$542
What the payments were for
- Consulting fees$1,10018%
- Speaking & faculty fees$1,02416%
- Food & beverage$1,82329%
- Education$1042%
- Other$2,16435%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $2,349 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,024 |
| E.r. Squibb & Sons, L.L.C. | 6 | $872 |
| Bristol Myers Squibb | 1 | $300 |
| Gilead(2 entities) | 7 | $251 |
| Merck | 6 | $175 |
| Seagen Inc. | 4 | $161 |
| Adaptive Biotechnologies Corporation | 1 | $150 |
| Karyopharm Therapeutics Inc. | 1 | $116 |
| Johnson & Johnson | 5 | $114 |
| Array Biopharma Inc | 4 | $74 |
| Exelixis Inc. | 3 | $73 |
| Eisai Inc. | 3 | $68 |
| Tempus AI, Inc | 3 | $61 |
| Sobi, Inc | 2 | $54 |
| AstraZeneca | 2 | $54 |
| Sanofi | 2 | $45 |
| GE HealthCare | 2 | $36 |
| Stemline Therapeutics Inc. | 1 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Genentech USA, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Pfizer | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Tesaro, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,215 in reported general payments places this provider in the 55th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 84 | $1,455,972 |
| PomalystPomalidomide | 49 | $997,922 |
| BrukinsaZanubrutinib | 66 | $777,954 |
| IbrancePalbociclib | 38 | $572,349 |
| ImbruvicaIbrutinib | 26 | $420,177 |
| TagrissoOsimertinib Mesylate | 25 | $409,458 |
| TibsovoIvosidenib | 12 | $378,921 |
| BosulifBosutinib | 18 | $372,279 |
| XtandiEnzalutamide | 28 | $316,274 |
| OrserduElacestrant Hcl | 12 | $303,109 |
| VerzenioAbemaciclib | 16 | $234,580 |
| JakafiRuxolitinib Phosphate | 13 | $204,057 |
| EliquisApixaban | 200 | $170,971 |
| MektoviBinimetinib | 12 | $125,495 |
| XermeloTelotristat Etiprate | 12 | $117,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $300 | $1,455,97284 claims |
| PfizerIbrance, Bosulif, Eliquis | $19 | $1,115,599256 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $872 | $997,92249 claims |
| AstraZenecaTagrisso | $54 | $409,45825 claims |
| Astellas Pharma US IncXtandi | $24 | $316,27428 claims |
| Stemline Therapeutics Inc.Orserdu | $31 | $303,10912 claims |
| Array Biopharma IncMektovi, Braftovi | $74 | $221,42924 claims |
| Incyte CorporationJakafi | $20 | $204,05713 claims |
| Johnson & JohnsonXarelto, Procrit | $114 | $57,03058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Savannah
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.